Literature DB >> 7671324

Bone marrow B lymphocyte development in c-abl-deficient mice.

J D Hardin1, S Boast, P L Schwartzberg, G Lee, F W Alt, A M Stall, S P Goff.   

Abstract

Mice homozygous for a mutation in the c-abl tyrosine kinase gene have multiple defects including high postnatal mortality, runting, morphological abnormalities, susceptibility to infections, and reductions in lymphocytes and their precursors. FACS analysis of bone marrow from mutant mice demonstrates variable reductions in pro-B and pre-B cells. While the numbers of cells in these populations are profoundly reduced in some mutants (16 and 1.2% of control pro-B and pre-B cells, respectively), normal levels are found in other individuals. In the affected mutants, some reductions are observed in many stages of B cell development. The response of B cell precursors to the cytokine interleukin-7 is variably affected while that of several other cytokines (stem cell factor, interleukin-3, GM-CSF, G-CSF, and erythropoietin) is normal in c-abl mutants. The population defects caused by the c-abl mutation can be recreated in normal mice by the transfer of adult bone marrow but, surprisingly, not fetal liver. These studies demonstrate that c-Abl signaling pathways may play a role in the earliest stages of B cell development in a developmental stage-specific manner. In spite of these variable abnormalities, however, the hemopoietic system of c-abl mutant animals is surprisingly intact.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671324     DOI: 10.1006/cimm.1995.1185

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  16 in total

Review 1.  Functional genomics of the murine immune system.

Authors:  H E Ruley
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  c-Abl-deficient mice exhibit reduced numbers of peritoneal B-1 cells and defects in BCR-induced B cell activation.

Authors:  Rachel A Liberatore; Stephen P Goff
Journal:  Int Immunol       Date:  2009-02-19       Impact factor: 4.823

3.  The effects of c-Abl mutation on developing B cell differentiation and survival.

Authors:  Hans Brightbill; Mark S Schlissel
Journal:  Int Immunol       Date:  2009-03-19       Impact factor: 4.823

4.  Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Authors:  Yashodhara Dasgupta; Mateusz Koptyra; Grazyna Hoser; Kanchan Kantekure; Darshan Roy; Barbara Gornicka; Margaret Nieborowska-Skorska; Elisabeth Bolton-Gillespie; Sabine Cerny-Reiterer; Markus Müschen; Peter Valent; Mariusz A Wasik; Christine Richardson; Oliver Hantschel; Heiko van der Kuip; Tomasz Stoklosa; Tomasz Skorski
Journal:  Blood       Date:  2016-02-10       Impact factor: 22.113

5.  Increased sensitivity to apoptotic stimuli in c-abl-deficient progenitor B-cell lines.

Authors:  M Dorsch; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

Review 6.  Abl tyrosine kinases in T-cell signaling.

Authors:  Jing Jin Gu; Jae Ryun Ryu; Ann Marie Pendergast
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

7.  T cell survival and function requires the c-Abl tyrosine kinase.

Authors:  Isabelle Silberman; Ronit Vogt Sionov; Valentina Zuckerman; Sue Haupt; Zehavit Goldberg; Andreas Strasser; Zami S Ben-Sasson; Michal Baniyash; Anthony J Koleske; Ygal Haupt
Journal:  Cell Cycle       Date:  2008-12-23       Impact factor: 4.534

8.  Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts.

Authors:  William D Bradley; Anthony J Koleske
Journal:  J Cell Sci       Date:  2009-10-01       Impact factor: 5.285

9.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

10.  Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis.

Authors:  Masayuki Iyoda; Kelly L Hudkins; Shirly Becker-Herman; Tomasz A Wietecha; Miriam C Banas; Shunhua Guo; Almut Meyer-Bahlburg; Jolanta Kowalewska; Gang Liu; Steven F Ziegler; David J Rawlings; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-11-19       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.